Summary
This 2022 study examined whether genomic biomarkers could reliably predict which bladder cancer patients would respond to cisplatin-based neoadjuvant chemotherapy. Drawing on multi-centre patient cohorts, the authors assessed the clinical utility of genomic signatures in stratifying treatment response and informing personalised oncology approaches. As suggested by the authorship and journal scope, the work contributes to precision medicine in urothelial cancer, though the abstract was unavailable for detailed assessment of specific biomarker performance.
UK applicability
Findings are directly applicable to UK bladder cancer management, as NHS oncology services increasingly adopt genomic profiling and personalised treatment protocols. However, implementation would require validation within UK treatment pathways and integration with existing diagnostic infrastructure.
Key measures
Genomic biomarker predictive accuracy, pathological complete response rates, recurrence-free survival, overall survival
Outcomes reported
The study assessed predictive genomic biomarkers for patient response to cisplatin-based neoadjuvant chemotherapy in bladder cancer. It evaluated the performance of genomic signatures in predicting treatment response and clinical outcomes.
Topic tags
Dig deeper with Pulse AI.
Pulse AI has read the whole catalogue. Ask about this record, its theme, or how the findings apply to UK farming and policy — every answer cites the underlying studies.